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CASPASE-12 (CASP12) has an anti-inflammatory function during infection, and is a risk factor for sepsis in 
African-Americans (AA). To determine if CASP12 could be protective for systemic lupus erythematosus (SLE) 
in AA, we genotyped AA SLE patients and controls. We found that, at best, there was a weak association 
between CASP12 genotype with the absence of anti-dsDNA autoantibodies in SLE patients. No effect was seen 
upon serum interleukin-1 beta levels, nor was any other protective effect noted for the CASP12 genotype, 
whether upon association with SLE, or any of the 11 American College of Rheumatology classification criteria.  
We concluded that CASP12 genotype thus does not influence the phenotype of SLE in AA. This raises the issue 
as to why this protein would not play a more significant role in a chronic inflammatory disease process. 
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Most humans lack a functional CASP12 gene. In all 
Caucasians and East Asians examined, and in 80% of people 
of African lineage [1, 2], The gene exists as a pseudogene 
(CASP12p1), the result of a premature termination mutation 
[3]. In approximately 20% of persons of recent African 
lineage, an intact gene is found where a single nucleotide 
polymorphism (#rs497116; A->G) converts the stop codon 
into one encoding Arg [1, 2].  
Intact CASP12 is a risk factor for sepsis in 
African-Americans in response to pro-inflammatory agents 
such as bacterial lipopolysaccharide. This is due to 
CASP12’s ability to down-regulate production of 
inflammatory cytokines such as interleukin (IL)-1β or tumor 
necrosis factor (TNF) and by interfering with the activation 
of the transcription factor NFκb [4, 5]. In African-Americans 
with severe sepsis, the mortality rate was 54% in individuals 
who carried CASP12, compared with 17% in individuals 
with possessed only CASP12p1. Knockout mice lacking 
CASP12 are also more resistant to sepsis and death than 
wild-type mice [6]. These anti-inflammatory activities are 
proposed to result from CASP12 biding to inflammasome 
components such as CASP1 and CASP5 [6] and/or to adaptor 
proteins downstream of pattern recognition molecules, such 
as NOD2 [7] or RIG-I [8]. 
The intact allele of CASP12 is still found in approximately 
20% of African-Americans, with higher allele frequencies in 
some populations in sub-Saharan Africans, and in some 
populations of Central and South Asians [1, 2, 9]. This implies 
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that despite its selective disadvantage, it may play a 
protective role in inflammatory processes exploited by 
specific pathogens [10].   
If CASP12 is a risk factor for sepsis, we posited that this 
allele would be protective against some inflammatory 
autoimmune diseases. If CASP12 causes a derangement in 
IL-1β or TNF production, individuals carrying the CASP12 
allele, but not CASP12p1, should be less likely to develop 
inflammatory disease. To test this hypothesis, we sought to 
determine if CASP12 genotype would have an effect upon 
the pathologic manifestations of systemic lupus 
erythematosus (SLE). To do so, we genotyped CASP12 in 
patients and controls from the Lupus Family Registry and 
Repository cohort [11], and assessed >714 patients and >300 
healthy controls.  
Patients had at least at least four of the 11 American 
College of Rheumatology (ACR) SLE classification criteria 
for SLE [12, 13]. We found that CASP12 genotype was neither 
a risk factor nor protective. CASP12 polymorphisms did not 
affect any of the 11 ACR classification criteria. In addition, 
there was no association between CASP12 genotype and 
clinical criteria in patients in a case-only design. That is, 
having or lacking CASP12 did not affect a patient from being 
susceptible to, or protected from any particular lupus 
manifestation, nor from combinations of the more severe 
diagnostic criteria, such as lupus nephritis plus 
neuropsychiatric symptoms. At best, we found a weak 
protective effect against the development of 
anti-double-stranded DNA antibodies, but no other 
autoantibodies, such as anti-Sm, -Ro, -La, -snRNP, and 
-cardiolipin).   
The first question arising is, what role, if any, does 
CASP12 play in autoimmune pathogenesis? In a previous 
study, we found that the presence of intact CASP12 had no 
overall effect upon the development of rheumatoid arthritis 
in AA, there was a subtle protective effect against the erosive 
pathologies of RA, as defined by radiographic changes of 
baseline joint erosion and joint space narrowing scores. 
Baseline joint narrowing and total disease scores were 
greater in CASP12p1 homozygous patients than those who 
were CASP12 homozygous. No significant differences could 
be identified for any other clinical parameters [14]. 
Given the reported downregulatory effects that CASP12  
exerts upon IL1β production via inhibition of CASP1 and 
subsequent IL1 β generation [4, 6], we expected to see reduced 
serum IL-1β levels in a genotype-dependent manner in our 
patient group, with the lowest levels in the CASP12 
homozygous patients. These expectations were predicated on 
the known defects in the ability of peripheral blood 
mononuclear cells to produce IL-1β occur in SLE patients [15] 
and the decreased IL-1β levels seen in patient serum [16]. In 
looking at any potential role of CASP12 in SLE, it is 
important to bear in mind that the contribution of IL1 to the 
pathogenesis of SLE is murky. In the murine lupus model, 
the NLRP3 inflammasome mediates lupus nephritis, with 
CASP1 playing a key role in the pathogenic process [17], and 
SLE patients show transcriptional upregulation of 
inflammasome component genes [18]. Yet this was not the 
case, although our small sample size makes us view this data 
with caution. 
The next question arising is whether CASP12 can 
influence the production of autoantibodies. The pathology of 
SLE is mediated by chronic autoantibody production (of 
which anti-dsDNA antibodies are the most important 
clinically [19, 20]) and immune complex deposition, which 
triggers inflammation and tissue destruction [21-23]. We 
observed a weak but significant effect on anti-dsDNA. Yet 
after adjusting for multiple testing in the case-control and 
case-case analyses, no significant results remained, and no 
significant effects were seen for the other autoantibodies.  
Given the role of CASP1 in the generation of autoantibodies 
[17], it is possible that an IL1-independent pathway is 
involved. 
How CASP12 exerts the protective effects described 
above is unknown. If CASP12 is downregulatory, it may fail 
to reduce serum concentrations of pathogenic cytokines 
driving autoantibody production below disease-inducing 
levels, but does so at the tissue or cellular level. This notion 
is supported by the observation that there is less macrophage 
infiltration into adipose tissues of obese African-American 
children who are CASP12-positive [24]. 
The above leads us to a third question: Is CASP12 actually 
anti-inflammatory? Saleh and colleagues extended their 
finding on CASP12 and IL1-β to other inflammatory 
cytokines with the observation that obese African-American 
children who are CASP12-positive have lower serum IL6 and 
C-reactive protein levels [24]. Unfortunately, these workers 
did not report on any findings concerning IL-1β or TNF. 
Perhaps then IL-1β is not triggered at a systemic level 
following metabolism-based inflammation, but instead is 
either activated by non-CASP1-mediated mechanisms in 
different disease states (reviewed in [25]) or IL-1β production 
is not affected by CASP12. We lean toward the latter 
interpretation.  
CASP12 genotype does not influence susceptibility or 
adverse events in African-Americans or black South Africans 
with community-acquired pneumonia [26]. In addition, the 
CASP12 allele does not affect susceptibility to Candida 
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sepsis in Africans, nor does it affect  serum inflammatory 
cytokine concentrations in the pathology of candidiasis [27] or 
in in vitro responses to Yersinia pestis [28]. While malaria 
would be an obvious candidate for a positive selective effect 
upon maintenance of CASP12, there is no association 
between CASP12 genotype and either the presentation of 
severe malaria or outcomes in individual clinical parameters 
in malaria patients [29]. 
CASP12’s effects upon TNF production, which is elevated 
in all lupus patients, especially African-Americans [30], is also 
contradictory [5, 28, 31]. Further, while hepatitis C virus is an 
IL-1β inducer [32], CASP12 genotype has no effect on the 
clearance of this pathogen [33]. Confounding the metabolic 
findings described above by Skeldon and co-workers, no 
protective effects are found in African-American adults with 
CASP12 when metabolic parameters or C-reactive protein 
levels were assessed.  
Our findings with two separate rheumatologic diseases 
bring us to the title of this review. In Sir Arthur Conan 
Doyle’s short story The Adventure of the Silver Blaze, the 
detective Sherlock Holmes noted that a guard dog was 
supposed to bark at prowlers in the night, yet didn’t do so 
prior to the occurrence of a crime. CASP12 is posited to 
downregulate inflammation mediated by cytokines, to such 
an extent that this activity renders a subject more susceptible 
to sepsis.  This would explain the near extirpation of the 
functional allele from the vast majority of the human 
population [1, 2]. However, it is worth noting two key effects 
observed by Vande Walle and colleagues in 
CASP12-knockout mice: they also lack CASP11, and 
restoration of the CASP-11 gene restores inflammatory 
immune function to these animals [34]. Hence, the 
down-regulatory effects of CASP12 on the inflammasome 
observed by Saleh and colleagues at best, appear not to be 
applicable to rheumatic disease in humans, and at the worst, 
may be artefactual. 
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